Based on the observation that the growth of solid tumors is dependent on the formation of new blood vessels, therapeutic strategies aimed at inhibiting angiogenesis have been proposed. A number of proteins with angiostatic activity have been described, but their development as therapeutic agents has been hampered by difficulties in their production and their poor pharmacokinetics. These limitations may be resolved using a gene therapy approach whereby the genes are delivered and expressed in vivo. Here we compared adenoviral delivery of endostatin, proliferin -related protein ( PRP ) , and interferon -inducible protein 10 ( IP10 ) genes. Recombinant adenoviruses carrying the three angiostatic genes express biologically active gene products as determined in vitro in endothelial cell proliferation and migration assays, and in vivo by inhibition of neoangiogenesis in rat chambers. Eradication of established tumors in vivo, in the murine B16F10 melanoma model in immunocompetent mice, was not achieved by intratumoral injection of the different vectors. However, the combination of intravenous plus intratumoral injections allowed rejection of tumors. Ad -PRP or Ad -IP10 were significantly more efficient than Ad -endostatin, leading to complete tumor rejection and prolonged survival in a high proportion of treated animals. These data support the use of in vivo gene delivery approaches to produce highcirculating and local levels of antiangiogenic agents for the therapy of local and metastatic human tumors. Cancer Gene Therapy ( 2001 ) 8, 45 ± 54
T he observation that solid tumors require angiogenesis for sustained growth was first made at the beginning of the last century. 1 Years later, Alguire 2 reported the capacity of tumors to elicit the formation of a new capillary endothelium. The concept of tumor angiogenesis was finally described by Folkman 3 who demonstrated that the growth of solid tumors from a localized neoplasm to an enlarging tumor, with the ability to metastasize, must be preceded by tumor neovascularization. Angiogenesis is a multistep process involving local proteolysis of the vascular basement membrane followed by migration, proliferation, and differentiation of endothelial cells leading to microtubule formation and sprouting of new capillary branches. 4 A tumor induces this proliferative vascular response from host vessels by altering locally the balance of pro -angiogenic factors such as VEGF, 5 FGFs, 6 and of endogenous angiogenesis inhibitors. The ability to modulate this``angiogenic switch'' by upregulating the release of angiostatic factors and downregulating the production of tumor-associated angiogenic factors should provide a means to disrupt the tumor via its vascular network. 7 Among the molecules already described as potential angiogenesis inhibitors, the most potent ones are fragments of larger inactive circulatory proteins namely endostatin, derived from collagen XVIII, or angiostatin, derived from plasminogen. 8, 9 Immunomodulatory molecules such as cytokines ( IL4, IL12, IFN ) or chemokines (PF4, IP10, MIG, SLC ) that are involved at the interface of the immune (T-and NK -cell recruitment to the tumor ) and nonimmune antitumor mechanisms ( angiostatic effect) also represent very interesting candidates due to their dual properties in stimulating a antitumor immune response combined with tumor vasculature destruction. 10 ± 14 Encouraging results with recombinant forms of angiostatin and endostatin produced in prokaryotic and eucaryotic cells have been reported. 15 ± 17 Although a recent study describes the efficient production of soluble endostatin in Pichia pastoris, heterologous production of soluble proteins such as endostatin without amino terminal heterogeneity and in large quantities for clinical trials remains difficult. 18 Direct in vivo gene transfer of antiangiogenic factors using viral or nonviral vectors may circumvent such problems. Recent studies using adenoviral vectors to deliver the angiostatin or endostatin genes have demonstrated some efficacy against tumor growth in athymic nude mice. 19 ± 22 Other studies described the angiostatic effects of chemokines, cytokines or urokinase fragments but did not compare the efficacy of these molecules to endostatin and /or angiostatin.
into tumor-bearing immunocompetent mice has so far not been described. Such model systems may probably be more relevant for the design of clinical trials in human patients.
In the present study, we have generated nonreplicative rAds that express three antiangiogenic factors, namely endostatin, proliferin -related protein ( PRP ), and interferon -inducible protein 10 ( IP10 ) to compare their in vitro properties and their in vivo effects in immunocompetent rats and mice. Endostatin, an M r 20,000 COOHterminal fragment of collagen XVIII purified from conditioned medium of the EOMA murine hemangioendothelioma cells, specifically inhibits the proliferation and migration of endothelial cells and induces their apoptosis. 16, 17 PRP is a murine placental protein that belongs to the prolactin and growth hormone family and is a strong inhibitor of endothelial cell migration. 28 ± 30 IP10, a member of the chemokine family, 31 inhibits bone marrow colony formation, 32 has antitumor activity in vivo, 33 ± 35 and suppresses endothelial cell differentiation in capillary tube formation. 36 Here, we showed that adenovirus -infected human microvascular cells produced large quantities of biologically active angiostatic proteins. These molecules were shown to specifically inhibit proliferation and /or differentiation of human microvascular endothelial cells. The effects of endostatin, PRP, and IP10 were then compared in fibrin gel chambers implanted in rats and finally their antitumor effects in B16F10 murine melanoma tumor cells were investigated.
MATERIALS AND METHODS

Cell culture
Murine melanoma cancer cell line B16F10 and human embryonic kidney cell line 293 were obtained from ATCC ( Rockville, MD ) and were maintained in Dulbecco's modified Eagle's minimal essential medium supplemented with 10% fetal bovine serum. Human dermal microvascular endothelial cells ( HDMEC, PromoCell, Heidelberg, Germany ) were cultured in specified medium (PromoCell ) between passage 2 and 6 according to the manufacturer's instructions. Before use, all cell lines were tested and found to be free of Mycoplasma infection.
Plasmid constructions
The murine endostatin, murine PRP, and human IP10 genes were inserted in the adenoviral shuttle plasmid as previously described by Erbs et al. 37 The plasmid pCR2.1 -BM40 -muEndostatin containing the murine endostatin gene inserted in frame with the BM -40 signal peptide was kindly provided by Dr. Clemens Lowik (Leiden University Medical Center, the Netherlands ). 38 The adenoviral shuttle plasmid containing the murine endostatin gene was constructed by using a SalI±XbaI fragment of this plasmid.
The human IP10 gene was constructed by oligonucleotide assembling using eight oligonucleotides covering the complete cDNA sequence of huIP10. 39 The first four oligonucleotides were assembled and cloned into the ScaI±XhoI site of pBK -RSV thus creating the 3 H part of human IP10. The resulting plasmid was sequenced and cut with SmaI±XmnI. The last four oligonucleotides were hybridized together, treated with klenow fragment, ligated, and inserted into the SmaI±XmnI site, thus generating the complete cDNA sequence of huIP10. A KpnI± huIP10 ± SpeI fragment was then transferred into the adenoviral shuttle plasmid.
The murine PRP cDNA 29 was generated from fetal placental tissue of B6D2 mice (Iffa-Credo, L'Arbresle, France) at day 12 of gestation. Total cellular RNA was isolated with RNANow (Biogentex Laboratories, Seabrook, TX ) and the PRP cDNA was amplified by RT-PCR using specific primers. The resulting fragment was cloned into EcoRI ±BamHI digested pBluescript KS + (Stratagene, La Jolla, CA ) and sequenced. An EcoRI± NotI fragment of the resulting plasmid was then cloned into the adenoviral shuttle plasmid.
Adenovirus production and titration
All recombinant adenoviral genomes were generated as infectious plasmids by homologous recombination in Esherichia coli as previously described. 40 The recombinant adenoviruses ( Ad -Endostatin, Ad -PRP, and Ad -IP10, expressing endostatin, PRP and IP10, respectively ) were generated by transfection into the 293 complementation cell line of the viral genomes released from their respective plasmids by PacI digestion. Virus propagation, purification, and titration of infectious units ( IU ) by indirect immunofluorescence of the viral DNA binding protein were carried out as previously described. 41 Purified viruses were stored in 1 M sucrose, 10 mM Tris ±HCl pH 8.5, 1 mM MgCl 2 , 150 mM NaCl, and 0.005% Tween -80. Adenovirus vector carrying an empty expression cassette was used as control (Ad-null).
Analysis of protein expression
HDMEC cells were infected in suspension at MOI 50 with adenoviral vectors as previously described 37 and cultured in complete medium containing 5% fetal calf serum (FCS ) for 24 hours. The cells were then rinsed twice with phosphate -buffered saline (PBS ) and cultured for 24 hours in reduced medium containing 5% FCS. The concentration of muEndostatin in cell supernatants was quantified by immunoassay ( Accucyte 2 murine Endostatin, Cytimmune Sciences, College Park, MD ) according to the manufacturer's instructions. Protein analysis by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS -PAGE ) of supernatants of infected HDMEC was performed. After recovering of bands from the gel, proteolytic peptides were sequenced by mass spectrometry.
2D gel analysis using 13-mm IPG strips (pH 60± 11 ) ( Pharmacia Biotech, Saclay, France ) for isoelectric focusing was performed with supernatant of Ad -endostatin± and Adnull ± infected HDMEC. 42 Briefly, to 100 L of the culture medium were added 120 mg of urea, 10 mg of CHAPS, 2.5 mg of DTE, and 5 L of IPG buffer 6 ± 11. The volume was adjusted to 250 L with water to obtain a final concentration of 8 M urea, 4% CHAPS, and 65 mM DTE. Samples were then run in the first dimension (isoelectric focusing ) at 50 kV hour and in the second dimension ( 12% SDS -PAGE ) until the front dye reached the bottom of the gel. Polyacrylamide gels were stained with colloidal Coomassie blue. 
Endothelial cell proliferation
HDMEC cells were infected in suspension at MOI 50 with adenoviral vectors 37 and cultured in complete medium containing 5% FCS for 24 hours. The cells were then trypsinized, counted, and resuspended at a concentration of 1Â10 4 cells /mL. Two hundred microliters of this cell suspension was then seeded into individual wells of a 96-well tissue culture plate. For each antiangiogenic molecule, 10 wells were plated either with or without addition of 50 ng /mL of recombinant VEGF ( R&D Systems, Minneapolis, MN ). Cell proliferation was measured using the CellTiter96 1 AQ ueous Assay (Promega, Madison, WI ). Five days after infection, the HDMEC were incubated with MTS (1 mg /mL ) for 1 hour and the optical density at 490 nm was determined. Results are expressed as the percentage of proliferation compared to control cells infected with empty adenovirus.
Endothelial tube formation on Matrigel
The inhibition of HDMEC tube formation by antiangiogenic molecules was evaluated on Matrigel (Becton Dickinson Labware, Bedford, MA ) . 44 Briefly, 1.5Â10 6 HDMEC cells were infected in suspension with adenoviral vectors 37 and cultured in complete medium containing 5% FCS for 24 hours. The cells were extensively washed with PBS and cultured for 48 hours. Subsequently, the growth medium was replaced with 1% FCS reduced specific medium supplemented with 100 g/mL heparin and antibiotics, and the cells were incubated for another 24 hours. The cells were trypsinized, counted, and resuspended in their respective medium at a concentration of 4Â10 4 cells /mL. The wells of 24 -well tissue culture plates were evenly coated with 250 L / well growth factor reduced Matrigel, which was allowed to solidify at 378C for 30 minutes. The cell suspensions were then plated into the Matrigel -coated wells and incubated for 8 hours at 378C. Tube formation was quantified by counting the number of connected cells in three randomly selected fields, using Â200 magnification, and image analysis on Adobe Photoshop software ( Adobe Systems, Seattle, WA ) .
Fibrin gel chambers implantation in rats
Adult Wistar rats with an average weight of 250 g were obtained from Iffa Credo (L'Arbresle, France ). Chambers were constructed as previously described. 45 Fibrin gel preparation. Forty microliters of culture supernatants from adenovirus ±infected HDMEC cells was added to 400 L rat fibrinogen and mixed with 0.2 NIH U /mL of human -thrombin ( Sigma, Saint -Quentin -Fallavier, France) in the presence of 3 mM CaCl 2 . Two hundred miroliters of this mixture was injected into individual chambers and polymerized at 378C overnight. Rats were anesthetized with pentobarbital and chambers were implanted in the dorsal subcutaneous space, the holes facing inward, toward the viscera. Cutaneous closure of the individual pocket formed for each chamber was realized with suture points. Depending on the experiment, rats received two or four chambers. Implanted chambers were removed 7 days after implantation and processed for microscopic examination.
Histological analysis. Chambers were removed and fixed in formaldehyde 4%. The fibrin gel was then removed from the chambers and embedded in paraffin. Transversal and longitudinal sections were performed to determine the number and size of the central and peripheral vessels as well the bud height. Serial sections of the fibrin gel were stained with hematoxylin ± eosin. For each bud, number and distribution of neovessels were measured on the histological sections using Â200 magnification and image analysis on Scion Image software (Scion, Frederick, MD ). 
In vivo experiments
Murine B16F10 tumor cells were trypsinized, washed, and resuspended in PBS at 3Â10 6 cells / mL. One hundred microliters of the cell suspension was then injected subcutaneously into the right flank of 6 -to 7 -week -old immunocompetent B6D2 mice. At days 7, 8, and 9 after injection of tumor cells, when tumors became palpable, the mice received three intratumoral (i.t.u.) injections of 1Â10 9 infectious units (IU) of adenoviruses diluted in 10 mM Tris ± HCl pH 7.5, 1 mM MgCl 2 . In the combination protocol, mice received one intravenous (i.v.) injection of 1Â10 9 IU of adenovirus vector at day 4 after tumor cell implantation, followed by intratumoral injections at days 7, 8, and 9.
Statistical analyses
The statistical difference in percentage of endothelial cell proliferation, endothelial tube formation, and rat vessel formation between the different groups was assessed using Student's t test (Microcal Origin 3.78 software, Microcal Software Inc., Northampton, MA ). The statistical difference in in vivo survival experiment between the different groups was assessed using Fischer's exact application (Statistica 5.1 software, Statsoft Inc., Tulsa, OK ) of the Kaplan -Meir survival curves. A P .05 was considered statistically significant.
RESULTS
Construction of recombinant adenoviruses expressing murine endostatin, murine PRP, and human IP10
The cDNA of murine endostatin, murine PRP, and human IP10 were inserted in an adenoviral shuttle plasmid under the control of the CMV promoter and containing the chimeric human -globin/ IgG intron and the SV40 late polyadenylation signal ( Fig 1 ) . The recombinant ÁE1 /ÁE3 replication -deficient adenoviruses vector genomes were generated by homologous recombination in E. coli and all viruses were amplified in 293 cells. HDMEC cells were infected with the different recombinant viruses and cell culture supernatants were collected for protein analysis ( Fig 2A ) . The expression of the angiostatic proteins was confirmed by SDS -PAGE. Their identity was confirmed by sequencing of proteolytic peptides of the protein bands by mass spectrometry. Figure  2A shows that PRP and endostatin are present in similarly high molar amounts in the cell culture supernatants. This may also be true for the much smaller IP10, although its low molecular mass and contaminating bands make this an approximative estimation.
For Ad -endostatin, 2D gel electrophoresis of infected cell supernatant revealed a single spot located at the correct molecular mass ( 20.3 kDa ) and pI (9.1 ) indicating that only one isoform of this protein is produced ( Fig 2B ) . Quantification of endostatin produced from Ad -endosta- RE Â GULIER, PAUL, MARIGLIANO, ET AL: ANTIANGIOGENIC THERAPY OF CANCER tin ± infected HDMEC cells was performed by immunoassay. Endostatin was produced in large quantities of 6700 200 ng /mL /24 hours /1Â10 6 cells. Protein expression was stable during the postinfection period with endostatin accumulating at 18900 1000 ng /mL /1Â10 6 cells after 72 hours. In vivo expression of endostatin was also evaluated after a single i.v. injection of 1Â10 9 IU Ad -endostatin into the tail vein of B6D2 mice ( five mice per group ). Five days after injection, blood was collected and analyzed by immunoassay. The circulating level of endostatin was 2200 400 ng /mL. In the control group, injected with empty adenovirus vectors, endostatin was below the detection limit. These results show that adenoviral transfer of antiangiogenic genes is feasible and allows high stable production of these molecules.
Biological activity of angiostatic molecules produced by adenoviral vectors in vitro
To evaluate the biological functions of the different recombinant angiostatic proteins, adenovirus -transduced HDMEC cells were tested in proliferation inhibition assays in the presence or absence of VEGF (Fig 3) . Under the conditions used, the proliferation of infected control cells increased by 88 17% in response to VEGF stimulation. Adendostatin derived supernatant did not inhibit proliferation of HDMEC cells in the presence or absence of VEGF even though the concentration of endostatin in the culture medium ( 6700 ng /mL) was 10 -fold higher than the inhibitory concentration described elsewhere. 46 However, this observation is consistent with other results showing no inhibitory effect of recombinant endostatin on proliferation of bFGFstimulated HUVEC cells. 38 Similarly, Ad -PRP ± infected HDMEC cells did not differ significantly in proliferation rate either in the presence or absence of VEGF compared to control cells. Only with Ad -IP10, the proliferation rate of infected cells was strongly inhibited. It decreased by 59 19% in the absence of VEGF and the effect was even stronger in presence of VEGF with a decrease of 78 4% compared to control cells.
The in vitro antiangiogenic activity of the three genes was further tested in a differentiation inhibition assay. Infected HDMEC cells were plated on a Matrigel surface and tube formation was monitored after 8 hours. Infected control cells showed well -defined tube formation with many connected cells ( Fig 4A ) . On the contrary, all cells infected with adenovirus vectors bearing angiostatic genes showed a clear inhibition in their ability to form tubes. Compared to control, the inhibition of differentiation was 55 1%, 57 3%, and 63 3% for Ad -endostatin ±, Ad -PRP ±, and Ad -IP10 ±transduced cells, respectively (Fig 4B) .
Biological activity of angiostatic molecules produced by adenoviral vectors in vivo
The in vivo antiangiogenic activity of endostatin, PRP, and IP10 was tested in fibrin gel chambers implanted in Wistar rats. The fibrin gel consists of 10% of supernatants of adenovirus -transduced HDMEC cells. This assay system allows studying developmental angiogenesis and is used to obtain an initial indication of angiostatic activity before in vivo testing in murine tumor models. As depicted in Figure  5A , microscopic examination of explanted chambers reveals inhibition of vessel formation by the three angiostatic proteins with a reduction of vessel number and size inside the buds. The degree of vessel formation was calculated by reporting the number of central and peripheral vessels to the bud diameter. Compared to control, endostatin, PRP, and IP10 significantly inhibited in vivo neoangiogenesis inside the bud by 38 8, 31 11, and 39 4%, respectively (Fig 5B) .
Systemic and intratumoral administration of adenoviral vectors expressing angiostatic genes leads to complete rejection of B16F10 tumors
To test whether Ad -endostatin, Ad -PRP, and Ad -IP10 could inhibit tumor growth, we used the murine melanoma tumor cell line B16F10. Initially we tested whether intratumoral injections of 1Â10 9 IU of the adenoviral vectors could induce regression of tumors which had a volume of approximately 10 mm 3 at the day of the first injection. As shown in Figure 6A , no significant effect was observed on tumor growth or on survival of mice treated with three intratumoral injections. Similarly, tumor rejection was not observed with higher vector doses ( up to 5Â10 9 infectious units), five instead of three vector injections, or with other tumor cell types ( data not shown ).
To optimize the delivery of angiostatic factors we combined i.v. and i.t.u. administration of the recombinant adenoviral vectors. I.v. administration of adenovirus leads to transduction mostly of liver cells and secretion of the protein product into circulation. 47 Figure 6B shows the effects of combined i.v. and intratumoral injections of the different vectors in mice bearing B16F10 pre -established tumors. With this injection protocol, 15% of Ad -endostatin ± treated animals rejected their tumors but this difference was not statistically significant. On the contrary, 33% and 42% of mice injected with Ad -IP10 or Ad -PRP completely rejected their tumors with a statistical significance of 0.05 and 0.03, respectively, compared to the control group. To our knowledge, these results represents the first evidence of adenoviral mediated cure of pre -established tumors in immunocompetent mice.
DISCUSSION
Under physiological conditions, new blood vessel formation is under homeostatic control via interplay between endogenous inducers and inhibitors of endothelial cell proliferation, invasion, migration, and capillary tube formation. 4 Whereas normally angiogenesis inhibitors predominate over inducers to maintain the control of angiogenesis, in tumors this balance may be disturbed through overexpression of inducers of angiogenesis and/ or down -regulation of inhibitors, thus allowing tumor expansion at the primary site and In the present study, we show that endostatin, PRP, and IP10 can be produced at high levels in adenovirustransduced cells, and we compared the angiostatic effects of these molecules in vitro on HDMEC.
In a Matrigel -based assay, all molecules were equally effective and inhibited endothelial cell differentiation in vitro. However, in a proliferation assay, only the IP10 chemokine had a potent inhibitory effect on microvascular cell proliferation, both in the presence or absence of VEGF. We did not observe any inhibitory effect of Ad -endostatin upon transduction of HDMEC, although these cells produce very high quantities of endostatin. This stands in contrast to reports describing inhibition of bovine capillary or coronary venular endothelial cell proliferation. 16, 46 However, other studies also reported this lack of effect of endostatin on HUVEC or HDMEC. 38 The differences observed may therefore be due to differences in sensitivity of different endothelial cell types to angiostatic molecules. 48 We then assessed the in vivo effect of endostatin, PRP, and IP10 in fibrin chambers implanted in rats, and against murine melanoma tumors established in immunocompetent mice. The fibrin chambers, compared to in vitro assays, allow the three -dimensional study of angiogenesis in a more complex situation, implying different cell types and conditions favoring more or less strongly neo-vessel formation. The antiangiogenic activity of the three different proteins, i.e., from supernatants of adenovirus -infected HDMEC, was assessed by measurement of the number, size, and bud height of central and peripheral vessels inside the chamber. Histological analysis of bud sections demonstrated significant inhibition of neo -angiogenesis compared to controls in this in vivo context. Among the three angiostatic proteins, however, no obvious differences were observed because they all had a similarly high inhibitory activity.
We then assessed the effect of these angiostatic genes on tumor growth. As a first approach, adenoviruses were injected directly into different pre -established murine tumors (RenCa renal carcinoma, B16F0 and B16F10 melanoma, LLC lung carcinoma, P815 mastocytoma ) with a mean volume of 10 ± 25 mm 3 . Despite high vector doses (up to 5Â10 9 IU ) little, if any, effect of the intratumorally injected viruses was observed ( data not shown ). Alternatively, single i.v. injection of adenoviral vectors was also assessed into mice bearing 7 days implanted tumors with no significant effect on tumor growth ( data not shown) . These observations are consistent with a recent study in which adenovirus mediated delivery of angiostatin was effective only in the early stage of tumor angiogenesis. 22 Also, it may be possible that different types of tumors secrete distinct sets of growth factors reducing the sensitivity of the tumor vasculature to angiostatic factors.
We therefore tested the combination of i.v. plus i.t.u. adenoviral delivery of endostatin, PRP, and IP10 to circumvent an eventual lack of endothelial sensitivity within the tumor microenvironment. I.v. administration of adenovirus and secretion of the protein product into the circulation 47 may eventually disturb the establishment of tumor before intratumoral treatment and prevent long -term metastases formation. After a single i.v. injection of Ad -endostatin, plasma endostatin levels reached over 2.2 g /mL, which is more than 60 times higher than previously reported for nonviral gene therapy. 49, 50 Nevertheless, even with such high concentrations, endostatin has little antitumoral effect whereas PRP and IP10 were much more potent in inhibiting the growth of these particularly aggressive melanoma tumors. Forty -two percent of the mice treated with Ad -PRP completely rejected their primary tumors. As opposed to previous studies of adenoviral delivery of antiangiogenic molecules, which described only transient effects on tumor growth, 19, 20, 22, 25, 51 we demonstrated here that complete rejection of tumors and prolonged survival of treated mice can be achieved with the appropriate dose and route of administration. This report also describes, for the first time, the use of PRP as an angiostatic antitumor agent and shows that it is more effective than endostatin and at least as effective as IP10.
Our results support adenovirus -mediated delivery of angiostatic genes as a strategy for the treatment of tumors and dormancy therapy of metastases in B6D2 mice bearing locally injected B16F10 tumors. However, the results also show that tumor size and route of administration are critical parameters influencing the efficacy of the treatment with different angiostatic factors. Intratumoral delivery may result in locally high expression of these molecules, but intratumoral injections alone failed to stop tumor growth, whereas high circulating amounts of antiangiogenic factors after i.v. plus i.t.u. injections were sufficient to cause tumor rejection. All together, these data suggest that the angiostatic activity of the three tested molecules may be restricted to early events of tumor vascularization. Both, in the rat chambers as well as after i.v. adenovirus vector injection, the antiangiogenic factors are present before or during early stages of the onset of neovascularization. All three molecules, evenly distributed through the matrix from the moment of implantation of these chambers, exert a certain inhibitory activity under the more or less weakly proangiogenic conditions. Tumors may produce additional angiogenesis promoting factors, and this difference might explain why Ad -PRP and Ad -IP10 are more efficient than Ad -endostatin in vivo.
Despite the possibility of eradicating primary tumors implanted in immunocompetent animals, systemic immunity was not induced by the treatment as demonstrated by the absence of protection after secondary tumor challenge (data not shown ). These observations emphasize the need of combining antiangiogenic agents with other therapies like radiotherapy, 52 ± 54 chemotherapy or immunotherapy to enhance antigen processing, tumor destruction, and systemic antitumor immunity.
